Symptom duration and resolution with early outpatient treatment of convalescent plasma for COVID- 19: a randomized trial.

Sheriza N BakshSonya L HeathYuriko FukutaDavid ShadeBarry MeisenbergEvan M BlochAaron A R TobianEmily S SpivakBela PatelJonathan GerberJay S RavalDonald ForthalJames PaxtonGiselle MosnaimShweta AnjanJanis BlairEdward CachayJudith S CurrierPiyali DasMoises HuamanCatherine SutcliffeAnusha YaravaArturo CasadevallDavid SullivanDaniel HanleyKelly A Gebonull null

Published in: The Journal of infectious diseases (2023)

In this trial of outpatients with early COVID-19, CCP was not associated with faster resolution of symptoms compared to control. Overall, there were no differences in the prevalence of each symptom or symptom clusters at day 14 by treatment.

Keyphrases

coronavirus disease
sars cov
clinical trial
risk factors
patient reported
physical activity
depressive symptoms
phase iii